FDA warns opioid repackers for "significant violations."
FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.
The validity of a new large study linking anticholinergic drugs to the risk of dementia has stirred up controversy.
FDA recalls insulin pumps due to cybersecurity miscommunication.
A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.
A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
The first FDA-approved device to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
FDA cleared the first-and-only calcitonin gene-related peptide (CGRP) antibody for cluster headaches.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.